Drug development company 180 Life Sciences has announced the selection of its lead synthetic CBD analogue to move forward into clinical development for medicines.
180 Life Sciences, a biotechnology company that develops novel drugs to meet unmet needs in inflammatory diseases, fibrosis and pain, has selected a lead synthetic CBD analogue that is expected to move forward in clinical development for medicines that treat inflammation and pain.
Scientists at 180 Life Sciences have identified the analogue as a lead molecule in the company’s SCA platform as part of a long-standing collaboration since 1998 with cannabis research pioneer Raphael Mechoulam at Hebrew University, Jerusalem and Sir Marc Feldmann’s Laboratory at Oxford University, UK.
HUM-217 development
The lead compound, named HUM-217, was selected based on a wide-ranging screen of derivatives of CBD and CBG made by Professor Mechoulam.
180 Life Sciences, which leverages the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University, says that HUM-217 appears to have a novel composition of matter which would enable patent protection, preclinical efficacy in mouse models for treating pain and inflammation in vivo and ease of scalability.
Professor Sir Marc Feldmann, 180 Life Sciences executive co-chairman, said: “It is a real pleasure to announce the progress that has been made, which we believe is a significant step forward towards the more effective use of pure synthetic cannabinoids in medicine. We look forward to continuing the development of these compounds in clinical trials.”
“We believe that our lead compound HUM-217, a CBD derivative generated by cannabis chemistry pioneer Professor Raphael Mechoulam, meets all the criteria desirable to advance to clinical development,” added Dr James Woody, 180 Life Sciences’ CEO. “We look forward to continuing to pursue new therapeutics for one of the world’s largest drivers of disease, Inflammation.”
The company is exploring HUM-217’s safety profile in greater detail.
[activecampaign form=31]
